Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
When Selin Ariç stepped into her role as co-owner and CEO of Doratek Medikal in 2020, she brought more than technical knowledge. She believed that every implant should serve not just the body, but the surgeon working with it. With a background in biology and a master’s in nanotechnology and nanomedicine, her career spanned quality systems, regulatory affairs and product development. What set her apart in every domain was her perspective. Too often, she observed, device design dictated surgical technique. Ariç asked a different question: ‘What if product design were adapted to real surgical challenges, instead of limiting them? That shift reframed Doratek’s development philosophy. Under her leadership, Doratek began prioritising clinical realities over manufacturing convenience. Feedback from surgeons became the foundation. As a result, the CE-certified orthopaedic device manufacturer now measures success not by the number of implants produced but by the surgical outcomes it helps achieve—minimal bone disruption, faster recovery and fewer revision procedures. “We are inspired to advance patient care. We’ve always believed that true innovation in orthopaedics requires not just high-performance products, but also a deeper understanding of unmet clinical needs, long-term partnerships and a sustained commitment to education and development,” says Ariç. Doratek now leads Turkey’s arthroscopy market with nearly 120 distributors nationwide and exports to 77 countries. Its portfolio spans arthroscopy and sports medicine, spinal systems, cranial and maxillofacial implants, toe prostheses, hallux valgus plates and headless compression screws, each designed to give surgeons procedural flexibility without compromise. The products comply with international quality standards and are certified by SGS Belgium. They are also approved by leading regulatory authorities, including ANVISA (Brazil), INVIMA (Colombia), COFEPRIS (Mexico), and the Ministry of Health in Ukraine. Its quality management system is ISO 13485 certified and a complete traceability system follows each implant, from raw material to post-surgical application, ensuring transparency and accountability at every stage.
The field of ophthalmology is on the cusp of a paradigm shift that holds the promise of revolutionising eye care. Espansione Group is at the forefront of this transformative shift. The medtech company is on a mission to improve the lives of patients with inflammatory eye conditions and assist healthcare professionals in diagnosing and treating them with ease with innovative, non-invasive light technologies. This includes Light Modulation Low-Level Light Therapy (LM LLLT) and Optimal Power Energy—an intense pulsed light technology (OPE IPL). The cutting-edge technologies eliminate patient concerns about the invasiveness of certain treatments and relieve physicians from time-consuming and complex procedures in existing eye care practice. The company’s trailblazing medical devices leverage these novel, patented technologies to optimise refractive and cataract surgeries while expanding into treatments for retinal diseases. Its product portfolio—comprising Eye-light, Meibomask, My-mask and Me-check—covers the entire value chain from diagnosis to treatment, potentially enhancing the quality of life for millions. Espansione has emerged as a global leader in addressing inflammatory eye surface diseases in more than 50 countries. Its impact extends beyond the technology application, driving the improvement of medical procedures involving vision care. “We invest in clinical and scientific R&D on degenerative eye conditions and light-based medical technologies to achieve the best objective outcome for patients and doctors,” says Luca Trimigno, executive board member and chief strategy and corporate development officer at Espansione Group. Its photobiomodulation technology, LM LLLT, is an advanced and refined version of an original NASAdeveloped patent that used invasive lasers. By evolving this concept with medical-grade light-emitting diodes and sophisticated software control, Espansione has successfully adapted this original idea for medical use in humans without any side effects or pain in ophthalmological applications. LM LLLT effectively targets degenerative conditions like meibomian gland dysfunction (MGD)—responsible for 80 percent of dry eye cases—and dry age-related macular degeneration (AMD) by emitting precise light frequencies.
Butterfly Network is rewriting the rulebook for point-of-care diagnostics by making cutting-edge ultrasound technology accessible, affordable and efficient. It aids healthcare professionals worldwide with handheld, portable, cloud-connected ultrasound devices that offer crystal-clear imaging. Following a mission to democratize ultrasound and empower doctors, it delivers tools for hospitals and educational institutions to improve diagnosis, treatment and patient outcomes. Whether in emergency medicine, critical care, OB/GYN, or primary care, Butterfly’s probes provide precise, user-friendly imaging solutions. Compass, a device-agnostic ultrasound workflow solution, streamlines the integration of these devices within healthcare institutions. It ingests scans from Butterfly probes and existing ultrasound devices, ensuring seamless deployment. Key features include customizable worksheets, automated data transmission to EMR and PACS, and quality assurance and proficiency management tools. It also supports documentation, billing and governance. Analytics dashboards provide actionable insights to optimize point-of-care ultrasound (POCUS) programs. At the heart of Butterfly’s innovation are the flagship iQ3 and iQ+ ultrasound systems, redefining traditional medical imaging. iQ3, a third-generation probe, delivers twice the processing power of its predecessors. It offers superior image quality and unmatched diagnostic precision with full-body imaging capabilities, allowing clinicians to make rapid, informed decisions at the point of care. iQ+ probe, Butterfly’s second-generation model, provides a versatile, handheld solution for various specialties, including cardiology and obstetrics. It comes with several imaging modes, including B-Mode, M-Mode, Color Doppler, and Power Doppler. B-Mode (2-D) provides high-resolution, real-time imaging of anatomical structures. M-Mode offers detailed motion visualization within a single scan line, which is essential for assessing cardiac and fetal heart rates. Color Doppler visualizes blood flow by indicating velocity and direction, while Power Doppler highlights blood flow amplitude, showcasing areas of increased vascularity. Pulsed-Wave Doppler measures blood flow velocity at specific locations, aiding vascular assessments. Together, these features make the iQ+ system an essential tool across specialties. iQ+ Bladder automates bladder volume calculations in seconds, streamlining urological assessments. iQ+ Vet, a multi-species imaging solution for rapid, high-quality diagnostics in animals, extends this impact to veterinary medicine.
Orthopedic
Christopher Kipps, Clinical Director of Research & Development, University Hospital Southampton NHS Foundation Trust
Endoscopy
Dr. Karl Marlowe, Chief Medical Officer, Oxford Health NHS Foundation Trust
Cardiovascular Devices
Gianluca Casali, Medical Director, Johnson & Johnson, MedTech UK & Ireland
Cardiovascular Devices
Greg Mtunz, General Manager Diagnostic Services, Buckinghamshire Healthcare NHS Trust
Cardiovascular Devices
Kolitha Basnayake, Deputy Medical Director, University Hospitals Birmingham NHS Foundation Trust
Endoscopy
Vratislava Kovarova, Senior Director Population Health and Medicine, Fresenius Medical Care
Orthopedic
Lars Blond, Senior Orthopedic Surgeon, Aleris Hospitals
Orthopedic Devices and instruments
Brad Johnson, VP, Orthopaedic Destination Service Line and Outpatient Rehabilitation Services, Stanford Health Care
Drug Delivery Solutions
Antoni Chan, Clinical Lead in Rheumatology, Royal Berkshire NHS Foundation Trust UK
As technology evolves, the future of orthopaedic care promises even more exciting possibilities for patients and healthcare providers.
Smarter Tools, Better Outcomes, European Made
Driving this shift is a demand for value—not just in terms of cost, but in patient outcomes. Health systems across Europe are aligning purchasing decisions with measurable results, forcing MedTech firms to evolve beyond hardware to offer full-stack solutions: devices, software, and support ecosystems bundled into seamless care experiences.
Yet innovation is only part of the equation. With environmental mandates tightening and supply chains under scrutiny, manufacturers are rethinking everything—from sustainable design to regional sourcing and more localized production. The winning formula now is not just tech-forward but eco-conscious, agile, and deeply responsive to clinician needs.
Doratek Medikal exemplifies this approach by producing high-quality neurosurgical and orthopedic implants locally, exporting to over 45 countries, and engaging directly with surgeons through hands-on training programs that support real-world adoption and better outcomes.
Global players are leaning in too. For example, Aleris, a leading private healthcare provider, is harnessing AI and digital platforms to streamline patient pathways and enhance diagnostic precision— offering a real-time look at how technology is redefining care delivery. Meanwhile, while Johnson & Johnson’s push into robotic-assisted surgery mirrors Europe’s appetite for smarter, less invasive procedures. Trends being shaped by these companies and others at the forefront of MedTech innovation.
Together, these efforts signal a MedTech sector in transformation— one that’s faster, smarter, greener, and closer to the patient than ever before. Europe isn’t waiting for the future of MedTech. It’s building it now.
